Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Antiviral Res ; 229: 105952, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38945484

RESUMEN

Argentine hemorrhagic fever, caused by Junín virus (JUNV), is the most common of the South American arenaviral hemorrhagic fevers. The disease has a case fatality rate of 15-30% in untreated patients. Although early intervention with immune plasma is effective, diminishing stocks and limited availability outside of Argentina underscores the need for new therapeutics. Ideally, these would be broadly active agents effective against all the pathogenic arenaviruses. The fusion inhibitor LHF-535 and the nucleoside analog favipiravir have shown promise in animal models of Lassa fever, a disease endemic in parts of Africa and the most prominent of the arenaviral hemorrhagic fevers. Against JUNV, a high dose of favipiravir is required to achieve protection in the gold-standard guinea pig infection model. Here, we demonstrate a synergistic effect by the coadministration of LHF-535 with a sub-optimal dose of favipiravir in guinea pigs challenged with JUNV. Administered individually, LHF-535 and sub-optimal favipiravir only delayed the onset of severe disease. However, combined dosing of the drugs afforded complete protection against lethal JUNV infection in guinea pigs. The benefits of the drug combination were also evident by the absence of viremia and infectious virus in tissues compared to guinea pigs treated with only the placebos. Thus, combined targeting of JUNV-endosomal membrane fusion and the viral polymerase with pan-arenaviral LHF-535 and favipiravir may expand their indication beyond Lassa fever, providing a significant barrier to drug resistance.


Asunto(s)
Amidas , Antivirales , Modelos Animales de Enfermedad , Virus Junin , Pirazinas , Pirazinas/farmacología , Pirazinas/administración & dosificación , Pirazinas/uso terapéutico , Animales , Cobayas , Amidas/farmacología , Amidas/uso terapéutico , Amidas/administración & dosificación , Virus Junin/efectos de los fármacos , Antivirales/farmacología , Antivirales/administración & dosificación , Antivirales/uso terapéutico , Fiebre Hemorrágica Americana/tratamiento farmacológico , Fiebre Hemorrágica Americana/virología , Quimioterapia Combinada , Femenino , Sinergismo Farmacológico , Infecciones por Arenaviridae/tratamiento farmacológico
2.
Expert Opin Drug Discov ; 19(5): 537-551, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38606475

RESUMEN

INTRODUCTION: Mammarenaviruses are negative-sense bisegmented enveloped RNA viruses that are endemic in Africa, the Americas, and Europe. Several are highly virulent, causing acute human diseases associated with high case fatality rates, and are considered to be significant with respect to public health impact or bioterrorism threat. AREAS COVERED: This review summarizes the status quo of treatment development, starting with drugs that are in advanced stages of evaluation in early clinical trials, followed by promising candidate medical countermeasures emerging from bench analyses and investigational animal research. EXPERT OPINION: Specific therapeutic treatments for diseases caused by mammarenaviruses remain limited to the off-label use of ribavirin and transfusion of convalescent sera. Progress in identifying novel candidate medical countermeasures against mammarenavirus infection has been slow in part because of the biosafety and biosecurity requirements. However, novel methodologies and tools have enabled increasingly efficient high-throughput molecular screens of regulatory-agency-approved small-molecule drugs and led to the identification of several compounds that could be repurposed for the treatment of infection with several mammarenaviruses. Unfortunately, most of them have not yet been evaluated in vivo. The most promising treatment under development is a monoclonal antibody cocktail that is protective against multiple lineages of the Lassa virus in nonhuman primate disease models.


Asunto(s)
Antivirales , Infecciones por Arenaviridae , Arenaviridae , Desarrollo de Medicamentos , Humanos , Animales , Antivirales/farmacología , Infecciones por Arenaviridae/tratamiento farmacológico , Infecciones por Arenaviridae/virología , Arenaviridae/efectos de los fármacos , Virulencia , Diseño de Fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA